AV-GBM-1

Published

dm+d

Unassigned

New Medicines

Newly diagnosed glioblastoma

Information

New molecular entity
AiVita Biomedical
AiVita Biomedical

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Cell-based therapy. Cancer stem cells from tumour sample are isolated, purified, inactivated and antigenic material is combined with dendritic cells which directs the immune system to eliminate malignant cells.[2]
Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor. Each year in the U.S. and Europe, two to three out of every 100,000 people are diagnosed with glioblastoma multiforme, which has a five year survival rate of approximately four percent.[1]
Newly diagnosed glioblastoma
Intravenous